Arcoxia is generically prescribed as etoricoxib and is commonly used in the treatment of osteoarthritis and arthritis pain. Arcoxia is a member of the family of drugs known as COX 2 inhibitors which selectively inhibits the pain receptors in the brain. Arcoxia was also designed to target and treat pain related to gout and rheumatoid arthritis.
Arcoxia has been denied use in the United States, although it has been in use in over 60 other countries. Arcoxia was denied use in the United States due to the lack of evidence that this medication was able to provide a high enough level of benefit considering the risks. Arcoxia belongs to the same family of medications that drugs such as Celebrex and Vioxx which were proven to have serious health effects including adverse cardiac and fatal cardiac reactions.
While proven effective at relieving inflammation and pain related to painful conditions, Arcoxia is said to provide onset of pain relief in under 30 minutes and last as long as 24 hours.
Patients with congestive heart failure, uncontrolled hypertension, peripheral arterial disease, ischemic heart disease, and cerebrovascular diseases are at a high risk of stroke or myocardial infarction. Patients with an elevated risk for heart complications such as diabetes, cigarette smoking, edema, pre-existing cardiac failure or a previous heart attack, and other general risk factors for heart problems should avoid the use of Arcoxia.
Arcoxia has been proven to cause hypertension, edema, and complications relating to edema in some patients. Any patients who experience sudden and rapid weight gain from the retention of fluid should seek immediate emergency medical attention.
There is a risk of patients developing a very serious and often fatal skin condition within the first 30 days of taking Arcoxia. Patients have been known to develop exfoliative dermatitis, toxic epidermal necrolysis, and Stevens-Johnson syndrome. Patients who develop a red, peeling, blistering rash especially when accompanied by a fever should seek immediate health care.
Arcoxia is not approved in any country for patients who are under the age of 16. Dosing for acute pain is only recommended for a maximum of 8 days. Arcoxia is not recommended for women who are pregnant, nursing, or who are attempting to conceive. It has yet to be determined whether or not Arcoxia passes through the mother’s breast milk and what affect it may have on a nursing infant. Arcoxia may or may not cause serious harm to a developing fetus. Arcoxia has not been approved in the United States for fetal testing or evaluation.
Arcoxia has been undergoing additional evaluation and testing through the companies responsible for producing it in order to gain approval in the United States. Arcoxia should not be prescribed with anticoagulants such as warfarin or Coumadin, and should not be prescribed as a long term solution for painful conditions. Arcoxia is not appropriate for patients who are lactose intolerant or who have lactose absorption issues. Diuretics, ACE inhibitors, and angiotensin II antagonists can lead to compromised renal function when taken with Arcoxia.
Generic name: Etoricoxib
Brand name(s): Algix, Nucoxia, Tauxib
Your Arcoxia review